Cargando…

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis

Bruton’s tyrosine kinase (BTK) inhibitors are an emerging class of drugs that inhibit B cell receptor activation, FC-γ receptor signaling, and osteoclast proliferation. Following on approval for treatment of hematologic malignancies, BTK inhibitors are now under investigation to treat a number of di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arneson, Laura C, Carroll, Kristen J, Ruderman, Eric M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409514/ https://www.ncbi.nlm.nih.gov/pubmed/34485183 http://dx.doi.org/10.2147/ITT.S288550

Ejemplares similares

Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
por: Schneider, Raphael, et al.
Publicado: (2022)

Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis
por: Shulga, Olga, et al.
Publicado: (2023)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Novel Bruton’s tyrosine kinase inhibitors currently in development
por: D’Cruz, Osmond J, et al.
Publicado: (2013)

Bruton’s Tyrosine Kinase Inhibition Promotes Myelin Repair
por: Martin, Elodie, et al.
Publicado: (2020)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)

Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus
por: Patsatsi, Aikaterini, et al.
Publicado: (2021)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

Role of Bruton’s tyrosine kinase in B cells and malignancies
por: Pal Singh, Simar, et al.
Publicado: (2018)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Khan, Abdullah Mohammad
Publicado: (2022)

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2023)

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
por: Roschewski, Mark, et al.
Publicado: (2020)

Tyrosine kinases in rheumatoid arthritis
por: Okamoto, Hiroshi, et al.
Publicado: (2011)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia
por: Ababneh, Obada, et al.
Publicado: (2022)

Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia
por: Montoya, Skye, et al.
Publicado: (2023)

Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
por: Chen, Jin-Shuen, et al.
Publicado: (2014)

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase
por: Ma, Hong, et al.
Publicado: (2013)

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells
por: Chang, Betty Y, et al.
Publicado: (2011)

Bruton’s Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease
por: Neys, Stefan F. H., et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
por: Lorenzo-Vizcaya, Ana, et al.
Publicado: (2020)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
por: Wang, Xianhui, et al.
Publicado: (2021)

Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies
por: Song, Yuqin, et al.
Publicado: (2023)

Bruton's tyrosine kinase inhibition—An emerging therapeutic strategy in immune‐mediated dermatological conditions
por: Mendes‐Bastos, Pedro, et al.
Publicado: (2022)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
por: Smith, C. I. Edvard, et al.
Publicado: (2021)

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
por: Neys, Stefan F. H., et al.
Publicado: (2021)

Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
por: von Hundelshausen, Philipp, et al.
Publicado: (2021)

Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies
por: Campbell, Robert, et al.
Publicado: (2018)

Bruton's Tyrosine Kinase Is Essential for Human B Cell Tolerance
por: Ng, Yen-Shing, et al.
Publicado: (2004)

A phase II study of Bruton’s tyrosine kinase inhibition for the prevention of anaphylaxis
por: Suresh, Ragha V., et al.
Publicado: (2023)

Amelioration of age‐related brain function decline by Bruton's tyrosine kinase inhibition
por: Ekpenyong‐Akiba, Akang E., et al.
Publicado: (2019)

The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives
por: Eyre, Toby A., et al.
Publicado: (2023)

Role of Bruton's Tyrosine Kinase in B Cell Development
por: Maas, Alex, et al.
Publicado: (2001)

Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care
por: Gillooly, Kathleen M., et al.
Publicado: (2017)

Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors
por: Naik, Piyu Parth
Publicado: (2022)

Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances
por: Wen, Tingyu, et al.
Publicado: (2020)

Bruton's Tyrosine Kinase: A Promising Target for the Treatment of COVID-19
por: Rezaei, Mitra, et al.
Publicado: (2020)

The Possible Role of Bruton Tyrosine Kinase Inhibitors in the Treatment of COVID-19: A Review
por: Rezaei, Mitra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9g37ik9540gk4ht8mhkbl37u5u